

August 18, 2020



# The Foundation for Angelman Syndrome Therapeutics (FAST) and Lixte Biotechnology Collaborate to Support the Preclinical Study of Lixte's Protein Phosphatase 2A Inhibitor, LB-100, as a Possible Treatment for Angelman Syndrome

EAST SETAUKET, NY, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ([OTCQB: LIXT](#)) announced an agreement with the Foundation for Angelman Syndrome Therapeutics (FAST) to collaborate in supporting preclinical studies of the potential benefit of Lixte's proprietary lead clinical compound, LB-100, in a mouse model of Angelman Syndrome (AS). The preclinical studies will be done at The University of California, Davis School of Medicine and MIND Institute under the direction of Drs. David Segal and Jill Silverman, internationally recognized leaders in AS research. If the preclinical studies confirm that LB-100 reduces AS signs in rodent models as reported in [The Proceedings of The National Academy of Science \(Wang et al, June 3, 2019\)](#), FAST and Lixte have agreed to enter into discussions of further collaborations to most efficiently assess the benefit of LB-100 in patients with AS.

Dr. John S. Kovach, CEO of Lixte, said "AS is a rare disease affecting approximately 20,000 persons in the US and approximately 500,000 worldwide. Its genetic cause, a mutation in a maternal gene called UBE3A, has been understood for some time but the molecular abnormality resulting from the genetic lesion has now been shown to be increased concentrations of protein phosphatase 2A (PP2A), the target of Lixte's investigational compound, LB-100. This was a completely unanticipated finding. We can only hope that LB-100 may be of benefit to patients afflicted with this devastating life-long disorder."

Paula Evans, the Chairperson for the Foundation for Angelman Syndrome Therapeutics commented, "FAST is excited to work with Lixte in pursuit of our mission to identify safe and effective therapeutics for Angelman syndrome. This collaboration is yet another example of

how a patient organization can offer a pharmaceutical company the tools and expertise necessary to evaluate therapies for a rare disease population.”

### **About FAST**

[FAST](#) is a Section 501(c)(3) non-profit research organization narrowly focused on funding research that holds the greatest promise of treating Angelman Syndrome. FAST is the largest, non-governmental funder of Angelman specific research.

To learn more about FAST's mission and funding priorities, or to make a donation towards FAST's research program visit [www.CureAngelman.org](http://www.CureAngelman.org).

### **About Lixte**

[Lixte](#) is a biotech company that identifies enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. Lixte's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or X-ray and immune checkpoint blockers.

### **Forward-Looking Statements**

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," "anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at <http://www.sec.gov/edgar.shtml>.

Additional information on the Company is available at [www.lixte.com](http://www.lixte.com).

Lixte Contact:  
(631) 830-7092  
[eforman@lixte.com](mailto:eforman@lixte.com)

FAST Contact  
Phone: (630) 852-FAST

Fax: (630) 852-3270  
Toll Free: (866) 783-0078  
Email: [info@CureAngelman.org](mailto:info@CureAngelman.org)



Source: Lixte Biotechnology Holdings, Inc.